Quarterly ResultAug 4, 2026, 04:13 PM
Rhythm Pharma Q2 Product Revenue Up 47% to $71.3M; Net Loss $49.3M
AI Summary
Rhythm Pharmaceuticals reported a significant increase in product revenue for the second quarter and first half of 2026. Q2 product revenue grew 46.9% to $71.3 million, and H1 product revenue increased 52.4% to $131.4 million. Despite this growth, the company's net loss widened to $(49.3) million for Q2 and $(104.9) million for H1, driven by increased operating expenses. The company ended the period with $330.9 million in cash, cash equivalents, and short-term investments, which management believes will fund operations for at least the next 24 months.
Key Highlights
- Q2 product revenue increased 46.9% to $71.3 million.
- H1 product revenue rose 52.4% to $131.4 million.
- Q2 net loss was $(49.3) million, compared to $(46.6) million last year.
- H1 net loss was $(104.9) million, up from $(96.1) million last year.
- Net cash used in operating activities improved to $(53.3) million for H1 2026.
- Cash, cash equivalents, and short-term investments totaled $330.9 million.
- Accumulated deficit reached $1.5 billion as of June 30, 2026.
- 72% of Q2 revenue was generated from a single US customer.
Price Impact
More from RYTM